- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05196178
Spinal Cord Stimulation Therapy for Hereditary Spastic Paraplegias Patients
Effects of Spinal Cord Stimulation Therapy on Motor Function and Gait in Patients With Pure Hereditary Spastic Paraplegias
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Pure hereditary spastic paraplegia is a heterogeneous group of genetic disorders characterized by degeneration of the corticospinal tracts, coursing with progressive weakness and spasticity of the lower limbs. The available anti spastic agents and surgical procedures involving anti-spastic systemic drugs, botulinum toxin, intrathecal baclofen, and even selective dorsal rhizotomy have not shown an improvement in muscle strength. Physical rehabilitation alone has shown positive results in short term, but this effect tends to fade away in few months.To date, there are no effective treatments for progressive deficits or disease-modifying therapy for Hereditary spastic paraplegia patients,
Spinal cord stimulation is a wellestablished therapy for the treatment of chronic neuropathic pain. Recently, some pilot studies demonstrated encouraging results of SCS in improving motor function. Patients severely affected by spinal cord injury experienced enhancements in leg movements and Parkinson's disease, primary progressive freezing of gait, and multiple system atrophy with predominant parkinsonism patients improved gait performance and freezing of gait after spinal cord stimulation by inducing changes in spinal and brain circuitry function. Some case studies suggest spinal cord stimulation may delay motor worsening and be innovative lines of research for the treatment of spastic paraplegia. However, evidence from larger numbers of subjects is still lacking. The objective of this study is to investigate the therapeutic effect and safety of spinal cord stimulation on motor function and gait in patients with pure hereditary spastic paraplegias
It's a single-center, prospective, open label clinical study with a 12 months follow- up period. The intended study population is individuals suffering from pure hereditary spastic paraplegia.Each participant will complete an enrollment/ screening/baseline visit, a spinal cord stimulation implant and activation visit, and a minimum of two follow-up visits, including visit at 3 months and the final study visit at 12months. The participants will proceed to implantation after satisfying implant inclusion and exclusion criteria. Paddle-shaped Spinal cord stimulation electrode with 16 contacts ((AdaptiveStim 39, 565; Medtronic, Minneapolis, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12. Electrode position will be verified by X-ray. The stimulators will be turned on within 1 month after electrode implantation surgery (slightly below sensory threshold). The stimulation parameters could vary freely, but medications will be kept constant during the study period. At the end of month 12, participants will enter the long-term follow-up in which medications and stimulation parameters could vary freely.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Beijing
-
Beijing, Beijing, Chine, 100053
- Recrutement
- Xuanwu Hospital,Capital Medical University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- aged between 14 and 70 years
- patients with pure hereditary spastic paraplegias
- with progressive weakness and spasticity of the lower limbs, and the gait dysfunction treatable by medication but not adequately controlled with medications
- Understand potential risk/benefit, consent to the study, study procedures, and agree to complete the study follow-up visits and comply with the study protocol requirements.
Exclusion Criteria:
- cognitive impairment ( MMSE≤24), depression (HAMD>24),acute psychosis, active alcohol or drug abuse, terminal illness, and any major medical or psychological histories, diagnoses, conditions, or comorbidities that would interfere with participation in the study per the investigatior's medical judgment
- surgical or medical contraindications to spinal cord stimulation surgery(e.g. uncontrolled hypertension, advanced coronary artery disease).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Spinal cord stimulation therapy
Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
|
Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
change in spastic paraplegia rating scale(SPRS)
Délai: twelve months after surgery
|
demonstrate the statistically significant improvement in score of spastic paraplegia rating scale(SPRS) from baseline( Off medication) to 12 months(On stimulation/Off medication); The score of SPRS ranges from 0 to 52, higher scores mean a worse outcome .
|
twelve months after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
change in the score of Modified Ashworth Scale
Délai: twelve months after surgery
|
demonstrate statistically significant improvement in score of Modified Ashworth Scale from baseline( Off medication) to 12 months(On stimulation/Off medication); The score of Modified Ashworth Scale ranges from 0 to 4, higher scores mean a worse outcome.
|
twelve months after surgery
|
change in Activities of Daily Living Scale (ADL)
Délai: twelve months after surgery
|
demonstrate statistically significant improvement in score of Activities of Daily Living Scale (ADL) from baseline to 12 months.
The score of ADL ranges from 0 to 100, higher scores mean a better outcome.
|
twelve months after surgery
|
change in Tinetti Balance and Gait Analysis
Délai: twelve months after surgery
|
demonstrate statistically significant improvement in the score of Tinetti balance and gait analysis from baseline( Off medication) to 12 months(On stimulation/Off medication); The score of Tinetti balance and gait ranges from 0 to 28, higher scores mean a better outcome.
|
twelve months after surgery
|
change in Berg Balance Scale(BBS)
Délai: twelve months after surgery
|
demonstrate statistically significant improvement in score of Berg Balance Scale(BBS) from baseline( Off medication) to On stimulation/Off medication state at 12 months.
BBS ranged from 0 to 56, higher scores mean a better outcome.
|
twelve months after surgery
|
Clinical Global Impression-Global Improvement
Délai: twelve months after surgery
|
Evaluations will performed in off-stimulation and in on-stimulation conditions at 12 months after surgery on the basis of the physician's assessment, as well as on the basis of the patients'selfreported satisfaction.
It is rated on a 7-point scale, range from 1(very much improved) through to 7 (very much worse)
|
twelve months after surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Yuqing Zhang, MD, Xuanwu Hospital, Beijing
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Manifestations neurologiques
- Anomalies congénitales
- Maladies génétiques, innées
- Maladies musculo-squelettiques
- Maladies musculaires
- Maladies neuromusculaires
- Maladies neurodégénératives
- Maladies du système nerveux périphérique
- Manifestations neuromusculaires
- Troubles hérédodégénératifs, système nerveux
- Malformations du système nerveux
- Paralysie
- Hypertonie musculaire
- Polyneuropathies
- Neuropathie sensorielle et motrice héréditaire
- Spasticité musculaire
- Paraplégie
- Paraplégie spastique, héréditaire
Autres numéros d'identification d'étude
- 20211116
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Démarche
-
Hadassah Medical OrganizationComplétéÉvaluer l'efficacité du Gait Trainer pour augmenter la fonctionnalité et les paramètres spatio-temporels de la marche de 4 patients.Israël
Essais cliniques sur Spinal cord stimulation
-
Tissue Tech Inc.ComplétéUlcères du pied diabétiqueÉtats-Unis, Canada
-
Technical University of MunichGerman Research FoundationComplétéDouleur expérimentale chez des sujets humains sainsAllemagne
-
Azienda Socio Sanitaria Territoriale degli Spedali...ComplétéAtaxie cérébelleuse | Atrophie multisystématisée | Ataxies spinocérébelleuses | Dégénérescences spinocérébelleuses | Ataxie spinocérébelleuse 3 | Ataxie de Friedreich | Ataxie spinocérébelleuse de type 1 | Ataxie spinocérébelleuse de type 2 | Ataxie spinocérébelleuse | Ataxie cérébelleuse | Ataxie avec...Italie
-
Technical University of MunichGerman Research FoundationComplétéDouleur expérimentale chez des participants humains en bonne santéAllemagne
-
Harbin Medical UniversityComplétéHernie inguinale, sans mention d'obstruction ou de gangrène
-
Azienda Socio Sanitaria Territoriale degli Spedali...ComplétéAtaxie | Atrophie multisystématisée | Ataxies spinocérébelleuses | Ataxie spinocérébelleuse 3 | Ataxie spinocérébelleuse de type 1 | Ataxie spinocérébelleuse de type 2 | Ataxie avec apraxie oculomotrice | TOILEItalie
-
InVivo TherapeuticsRésiliéLésion traumatique aiguë de la moelle épinière thoraciqueÉtats-Unis
-
University Hospital, ToulouseComplété
-
InVivo TherapeuticsRetiréBlessure aiguë traumatique de la moelle épinière cervicaleCanada
-
Ataturk Training and Research HospitalComplété